We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Nemolizumab improved atopic dermatitis-induced lesions ...

Please provide your email address to receive an email when new articles are posted on . Regulatory authorities in four countries have accepted nemolizumab filings indicated for prurigo nodularis and ...

NEMLUVIO is the first authorized monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31. 1 IL-31 is a neuroimmune cytokine that drives itch and is ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma announced positive data from three pivotal phase III trials in atopic dermatitis and prurigo nodularis – ARCADIA 1 and 2 and OLYMPIA 1, respectively. The ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and ...

The European Commission has approved nemolizumab (Nemluvio) for subcutaneous use in treating moderate to severe atopic dermatitis (AD) in patients aged ≥ 12 years and moderate to severe prurigo ...

Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements ...

Demonstrates Long-Term Disease Control In Prurigo Nodularis Up To Three Years - AETOS....(BUSINESS WIRE )--Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study inv ...

The FDA has granted nemolizumab Priority Review for the treatment of prurigo nodularis. The Food and Drug Administration (FDA) has accepted for review the Biologics License Applications (BLA) for ...

The recent safety update led Kyowa Kirin and Amgen to conclude potential risks may outweigh benefits for patient populations.

(RTTNews) - Galderma Group Ltd Canada (GALD.SW) shared on Monday that Health Canada has given the green light to NEMLUVIO, which is the first biologic treatment specifically for moderate-to-severe ...

Atopic dermatitis and prurigo nodularis are debilitating skin conditions that significantly affect quality of life, with symptoms such as persistent itch, skin lesions and poor sleep quality. 7-13 ...